Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joel Greshock

Showing results (31-40 of 56) with videos related to

Pageof 6
Sort By:
Oncology Reports|May 28, 2013
Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft modelsWenmin Hou, Xia Qin, Xuehua Zhu, et al.
Clinical Breast Cancer|July 16, 2008
Method of primary tumor detection as a risk factor for local and distant recurrence after breast-conservation treatment for early-stage breast cancerJulia Tchou, Joel Greshock, Meredith R Bergey, et al.
European Urology|August 14, 2016
Targeted Exome Sequencing of the Cancer Genome in Patients with Very High-risk Bladder CancerThomas Longo, Kathleen F McGinley, Jennifer A Freedman, et al.
Cancer Medicine|February 26, 2025
Prognostic Impact of Oncogenic Fibroblast Growth Factor Receptor Alterations in Patients With Advanced Solid Tumors in a Real-World SettingLevon Demirdjian, Spyros Triantos, Kristopher Standish, et al.
Cancer Research|November 8, 2011
A combined array-based comparative genomic hybridization and functional library screening approach identifies mir-30d as an oncomir in cancerNing Li, Sippy Kaur, Joel Greshock, et al.
Genome Research|February 6, 2004
High-resolution analysis of DNA copy number using oligonucleotide microarraysGraham R Bignell, Jing Huang, Joel Greshock, et al.
Molecular Cancer Therapeutics|June 24, 2010
Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instabilityYan Degenhardt, Joel Greshock, Sylvie Laquerre, et al.
Nature Communications|June 1, 2024
Development and deployment of a histopathology-based deep learning algorithm for patient prescreening in a clinical trialAlbert Juan Ramon, Chaitanya Parmar, Oscar M Carrasco-Zevallos, et al.
Genes, Chromosomes & Cancer|May 13, 2011
Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcomeJia Huang, Lin Zhang, Joel Greshock, et al.
Cancer Research|October 8, 2009
Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinasesFawn Qian, Stefan Engst, Kyoko Yamaguchi, et al.
Pageof 6

Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
Oncology Reports|May 28, 2013
Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft modelsWenmin Hou, Xia Qin, Xuehua Zhu, et al.
Clinical Breast Cancer|July 16, 2008
Method of primary tumor detection as a risk factor for local and distant recurrence after breast-conservation treatment for early-stage breast cancerJulia Tchou, Joel Greshock, Meredith R Bergey, et al.
European Urology|August 14, 2016
Targeted Exome Sequencing of the Cancer Genome in Patients with Very High-risk Bladder CancerThomas Longo, Kathleen F McGinley, Jennifer A Freedman, et al.
Cancer Medicine|February 26, 2025
Prognostic Impact of Oncogenic Fibroblast Growth Factor Receptor Alterations in Patients With Advanced Solid Tumors in a Real-World SettingLevon Demirdjian, Spyros Triantos, Kristopher Standish, et al.
Cancer Research|November 8, 2011
A combined array-based comparative genomic hybridization and functional library screening approach identifies mir-30d as an oncomir in cancerNing Li, Sippy Kaur, Joel Greshock, et al.
Genome Research|February 6, 2004
High-resolution analysis of DNA copy number using oligonucleotide microarraysGraham R Bignell, Jing Huang, Joel Greshock, et al.
Molecular Cancer Therapeutics|June 24, 2010
Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instabilityYan Degenhardt, Joel Greshock, Sylvie Laquerre, et al.
Nature Communications|June 1, 2024
Development and deployment of a histopathology-based deep learning algorithm for patient prescreening in a clinical trialAlbert Juan Ramon, Chaitanya Parmar, Oscar M Carrasco-Zevallos, et al.
Genes, Chromosomes & Cancer|May 13, 2011
Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcomeJia Huang, Lin Zhang, Joel Greshock, et al.
Cancer Research|October 8, 2009
Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinasesFawn Qian, Stefan Engst, Kyoko Yamaguchi, et al.
Pageof 6